The "T-cell Therapy Market by Modality, by Therapy (CAR T-cell, T Cell Receptor, and Tumor-Infiltrating Lymphocytes), by Indication, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
The T-cell therapy market size is estimated to be USD 4,748.5 million in 2022 and is expected to witness a CAGR of 20.33% during the forecast period 2023-2033. Increase in product approvals and rise in advanced manufacturing facilities are some of the factors contributing to the market growth.
Furthermore, escalating investments in the gene therapy and rise in collaboration with in various companies and institutes in the gene therapy are other factors supporting the market growth. However, inadequate reimbursement and high costs is expected to hinder the growth.
Increase in product approvals is predicted to propel the market growth during the forecast period. The strategic initiatives made in T-cell therapy area by public and private organizations are expected to fuel the market. For instance, in September 2020, the US FDA approved the IND application for ALVR109 to treat COVID-19 patients.
Additionally, due to the global COVID-19 pandemic, the increasing use of T-cell therapy in the treatments for viral infections is increasing the funding for T-cell therapies. For instance, in December 2020, the European Medicine Agency issued a marketing authorization to Kite Pharma's Tecartus - the only CAR-T therapeutic product for mantle cell lymphoma.
Rise in collaboration with in various companies and institutes in the gene therapy is predicted to propel the growth of market during the forecast period. For instance, the company Novartis AG collaborated with University of Pennsylvania for exploring the potential of CAR-T-based gene therapies for several chronic diseases. Additionally, as more than 350 CAR-T clinical trials had been registered in China, T-cell-based mechanisms are broadly used in cancer immunotherapy in June 2020.
Segmentation
By Modality
The market is bifurcated into research and commercial. In 2022, the research segment is accounted for the highest revenue share during the forecast period owing to the high number of products in the clinical development phase. The research institutes such as Mayo Clinic is actively engaged in conducting CAR-T therapy program supporting the method of cancer management. For instance, Immuneel Therapeutics collaborated with Institut d'Investigacions Biomediques August Pi i Sunyer and Hospital Clinic de Barcelona for the development and commercialization of CAR-T therapy in India in October 2020. On the other hand, the commercial segment is anticipated to exhibit the fastest CAGR during the forecast period. The regulatory bodies are making focused efforts to propel the commercial use of these therapies in clinical and hospital settings. For instance, the Centers for Medicare and Medicaid Services (CMS) policies for reimbursement and coverage of CAR-T cell therapy in September 2021.
By Therapy
The market is divided into CAR T-cell, T cell receptor (TCR), tumor-infiltrating lymphocytes (TIL). In 2020, CAR T-cell therapy segment accounted for the largest revenue share in 2022 owing to the exponential rise in the number of clinical trials for CAR-T therapies. The number of research institutes and academic institutions are conducting clinical trials for CAR-T therapeutic products for indications is expected to grow the segment's growth. For instance, the United States Food and Drug Administration (USFDA) recently approved T-cell therapies to treat children with acute lymphoblastic leukemia (ALL) and adults with advanced lymphomas. Additionally, T-cell receptor-based therapies segment is accounted to grow at fastest CAGR during the forecast period owing to their potential in the treatment of solid tumors. For instance, in February 2022, Medigene and BioNTech Announced Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer.
By Indication
The market is categorized into solid tumors (liver cancer, melanoma, brain & central nervous system) and hematologic malignancies (lymphoma, myeloma, leukemia). In 2022, the hematologic malignancies segment is expected for the highest revenue share during the forecast period. The CAR-T-cell therapies are used to treat hematological malignancies including lymphoma, leukemia, and myeloma. For instance, in 2022, there are six CAR-T cell products approved by the US Food and Drug Administration (FDA) for the treatment of R/R B cell malignancies, including tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel, which target the most common target antigens CD19 and B cell maturation antigen. Additionally, the solid tumor segment is predicted to grow at fastest CAGR during the forecast period. Many competitors are now focusing on the development of treatments for solid tumors. For instance, Seattle Genetics and Merck announced strategic oncology collaborations for investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for solid tumors. The development of affordable and effective therapy for solid tumors provides lucrative growth of the market.
Regional Markets
In 2022, North America region accounted for the highest revenue in the T-cell therapy market during the forecast period. This is attributed to the extensive research and commercial base for a number of clinical trials being conducted for T-cell therapies and cancer immunotherapy in the U.S Increase in number of regulatory approvals in the U.S and Canada along with the changing reimbursement in the region is anticipated to boost the market growth. In addition, the presence of a significant number of medical facilities offering CAR-T cell therapies also supports the regional market growth. Asia-Pacific is anticipated to grow at quickest CAGR during the forecast period. China has emerged the highest number of registered clinical trials for CAR-T therapies. Focused efforts on government investment and reforms in the country are predicted to propel the market growth. For instance, in China more than 350 CAR-T clinical trials have been registered which indicates the growing importance of Chimeric Antigen Receptor therapy in cancer treatment in June 2020.
Segmentation: T-cell Therapy Market Report 2022 - 2033
By Modality (Revenue, USD Million), 2022 - 2033
- Research
- Commercial
By Therapy (Revenue, USD Million), 2022 - 2033
- CAR T-cell
- T Cell Receptor (TCR)
- Tumor-Infiltrating Lymphocytes (TIL)
By Indication (Revenue, USD Million), 2022 - 2033
Solid Tumors
- Liver Cancer
- Melanoma
- Brain & Central Nervous System
Hematologic Malignancies
- Lymphoma
- Myeloma
- Leukemia
A selection of companies mentioned in this report includes
- Juno Therapeutics
- Novartis AG Merck KGaA
- Adaptimmune
- NantKwest
- Cabaletta Bio
- TCR2 Therapeutics Inc
- Celgene Corporation Bellicum Pharmaceuticals
- TScan Therapeutics
- GigaGen
- Fate Therapeutics Tessa Therapeutics
- Gilead Sciences Inc.
- Sorrento Therapeutics
- Bluebird Bio Inc.
- Pfizer Inc.
- Amgen
For more information about this report visit https://www.researchandmarkets.com/r/dy4yao-cell-therapy?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005798/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
